canada clinical guidance

Eczema (atopic)

A Canadian clinical summary of eczema (atopic), with source-attributed priorities and explicit jurisdiction boundaries.

JurisdictionCanada
Source check2026-08-20
Clinical reviewiatroX editorial team 路 Clinical editorial review 路 reviewed 2026-08-20 路 due 2027-08-20
AudienceHealthcare professionals practising in Canada
This is an iatroX educational summary of named Canada sources, not an official guideline. It does not replace the complete source documents, local policy, specialist advice or clinical judgement. The evidence source is pan-Canadian, but formularies, funded access, referral routes, public-health directions and service availability remain provincial or territorial.

Source and scope

This summary is bounded to the recommendations, population and decisions covered by Canadian Consensus Guidelines for the Management of Atopic Dermatitis with Topical Therapies. Apply it with the current provincial or territorial pathway where implementation differs.
sources for this section:Canadian AD consensus

Source-attributed clinical priorities

  • Confirm an atopic pattern while considering contact dermatitis, scabies, psoriasis, fungal infection and immune deficiency.
  • Use regular emollient care, trigger reduction and topical anti-inflammatory treatment matched to site and severity.
  • Recognize bacterial or herpetic infection, sleep loss and treatment burden and refer severe or uncontrolled disease.
  • Written instructions should specify which topical product goes on which body site and for how long.
sources for this section:Canadian AD consensus

Practical assessment and management workflow

1
Assess distribution, severity, itch, sleep, infection, triggers, occupational exposure and previous treatment.
2
Examine for atopic morphology and alternatives such as contact dermatitis, scabies, psoriasis or tinea.
3
Use liberal emollient care and site-appropriate topical anti-inflammatory treatment with application teaching.
4
Review adherence and potency before escalation and refer severe or treatment-refractory disease.
sources for this section:Canadian AD consensus

Safety, red flags and urgent escalation

  • Painful monomorphic vesicles, fever or rapidly worsening eczema suggests eczema herpeticum.
  • Treat spreading bacterial infection when clinically present, not colonization alone.
  • Avoid potent topical corticosteroid on thin skin without a defined short course and review.
sources for this section:Canadian AD consensus

Confirm the local pathway before acting

The evidence source is pan-Canadian, but formularies, funded access, referral routes, public-health directions and service availability remain provincial or territorial.
sources for this section:Canadian AD consensus

Source and implementation boundary

Read this educational summary with the linked source, current Canadian product information where medicines are involved, and the applicable provincial or territorial pathway. Local formularies, reporting duties, referral routes and service availability can differ.
sources for this section:Canadian AD consensus

Source documents

Use the linked source documents for complete recommendations, evidence grading, exclusions and implementation detail.

  1. Canadian Atopic Dermatitis Consensus PanelCanadian Consensus Guidelines for the Management of Atopic Dermatitis with Topical Therapiesaccessed 2026-08-20
    view source
continue the learning

From guidance to deliberate practice and evidence

Choose what happens next. iatroX can carry this page's jurisdiction, source-check date and released version into an editable learning record, support your reflection, or let you browse the regional question bank while keeping this topic visible. No action records completion, starts a session or awards CPD/CME credit automatically.

Found a source update or regional discrepancy? Tell the iatroX editorial team.